Abstract Details

Title Cognitive and Behaviorial Features of COVID-19 Patients in Post-Acute Phase

Topic Infectious Disease

Presentation(s) Infectious Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 071

Objective

To explore cognitive/behavioral features within two months from hospital discharge in a cohort of patients with COVID-19.

Background Although the epidemiological and clinical features of COVID-19 patients are well characterized, the psychological impact of SARS-CoV-2 has been given little attention.

Design/Methods 49 patients with confirmed COVID-19 underwent neuropsychological assessment within two months from hospital discharge. The presence of mood alterations and/or features of post-traumatic stress disorder (PTSD) was also investigated. The total sample was split based on age (yC-19, age<50: N=8; mC-19, age range 50-64: N=21; oC-19, age>65: N=20) and the frequencies of cognitive and behavioral alterations were reported for the total sample and each sub-group. Correlations were tested between neuropsychological scores and the severity of respiratory symptoms at hospital admission.

Results

5 patients (1 yC-19, 4 mC-19) presented with depressive symptoms and 9 (3 yC-19, 4 mC-9, 2 oC-19) reported PTSD features. 45% of the total sample showed executive dysfunctions and difficulties in encoding new verbal material; 30% showed visuospatial difficulties, and 25% long-term verbal and nonverbal memory problems. No patients showed language disturbances. Specifically, the yC-19 group showed the worst profile, with 60-75% patients showing executive dysfunctions and encoding difficulties, 50% pure visuospatial dysfunctions and 40% primary long-term memory problems. The mC-19 group showed primary executive (>40%) and visuospatial (25%) dysfunctions. 40% of the oC-19 group showed executive dysfunctions, 30% poor visuospatial abilities, and 25% long-term memory problems. The total sample showed a negative relationship between frontal executive performances and severity of acute-phase respiratory symptoms at hospital admission.

Conclusions

Within two months from hospital discharge, cognitive/behavioral alterations are associated with COVID-19 infection, with more severe outcomes in the youngest group. Whether these alterations are linked with the infection itself or with its related consequences has to be determined, as well as whether they are reversible or part of a neurodegenerative process.

Authors/Disclosures
Veronica Castelnovo, MSc (San Raffaele Scientific Institute, Vita-Salute San Raffaele University) PRESENTER	Dr. Castelnovo has nothing to disclose.
Elisa Canu (Ospedale San Raffaele)	The institution of Elisa Canu has received research support from Italian Ministry of Health .
Federica Agosta (San Raffaele Scientific Institute)	Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
	No disclosure on file
	No disclosure on file
Giordano Cecchetti (San Raffaele Hospital)	Giordano Cecchetti has nothing to disclose.
	No disclosure on file
	No disclosure on file
Monica Falautano (Ospedale San Raffaele)	Monica Falautano has nothing to disclose.
	No disclosure on file
	No disclosure on file
Massimo Filippi, MD, F�鶹��ýӳ�� (Ospedale San Raffaele, Neuroimaging Research Unit)	Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.

�鶹��ýӳ��

�鶹��ýӳ��